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ABSTRACT
Introduction: Atopic dermatitis (AD) has been
related to a deficiency of delta-6-desaturase, an
enzyme responsible for the conversion of
linoleic acid to gamma-linolenic acid (GLA).
Evening primrose oil (EPO) contains high
amounts of GLA. Therefore, this study
investigated whether EPO supplementation
results in an increase in plasma GLA and its
metabolite dihomo-gamma-linolenic acid
(DGLA) correlating with clinical improvement
of AD, assessed by the SCORing Atopic
Dermatitis (SCORAD) index.
Methods: The open study included 21 patients
with AD. EPO (4–6 g) was administered daily for
12 weeks. Before treatment, and 4 and 12 weeks
after initiation of EPO supplementation,
objective SCORAD was assessed and plasma
concentrations of GLA and DGLA were
determined by gas chromatography.
Results: A significant increase in plasma GLA
and DGLA levels and a decrease in the objective
SCORAD were observed 4 and 12 weeks after
initiation of EPO treatment. In the per-protocol
population (n = 14), a significant inverse
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correlation between the changes in plasma GLA
levels and SCORAD was found (P = 0.008).
Conclusion: The clinical disease activity under
EPO treatment correlates with the individual
increase in plasma GLA levels. Thus, the results
of this pilot study indicate that an increase in
plasma GLA might be used as predictive
parameter for responsiveness of AD to EPO
therapy.
Keywords: Atopic dermatitis; Dermatology;
Dihomo-gamma-linolenic acid; Evening
primrose oil; Gamma-linolenic acid; Omega-6
fatty acids; SCORAD
INTRODUCTION
Atopic dermatitis (AD) is a chronic
inflammatory skin disorder characterized by
eczematous lesions, skin dryness, and severe
itch [1]. AD affects 15–30% of children and
2–10% of adults [1]. The etiopathology of AD is
multifactorial and includes a genetic
predisposition towards disrupted skin barrier
function and allergic inflammation as well as
environmental factors [2]. Defects of the skin
barrier (e.g., due to mutations of the filaggrin
gene) lead to an increased irritability followed
by inflammatory processes [3].
At least in a subset of patients with AD, a
malfunction of delta-6-desaturase seems to play
a pathogenetic role [4]. This enzyme is
responsible for the conversion of linoleic acid
(LA) to gamma-linolenic acid (GLA), which is
further metabolized to dihomo-gamma-
linolenic acid (DGLA). DGLA is the precursor
of prostaglandin E1 (PGE1) or
15-hydroxyeicosatrienoic acid (15-HETrE) [5].
As a result of a reduced enzyme activity of delta-
6-desaturase, high levels of LA and low levels of
GLA have been observed in AD patients [6].
Accordingly, less DGLA and its metabolites
PGE1 and 15-HETrE known to have anti-
inflammatory capacity are produced [5].
Supplementation with GLA, a component of
evening primrose oil (EPO), is assumed to lead
to increased concentrations of GLA and DGLA
in blood, thereby supporting anti-inflammatory
responses [7]. Indeed, GLA supplementation
studies in humans and rodents have shown
that the synthesis of anti-inflammatory PGE1,
but not pro-inflammatory PGE2, was selectively
elevated [8].
The EPO preparation used in this study
contained high amounts of GLA (80 mg/
1,000 mg EPO) with sufficient bioavailability
after oral intake [9]. The clinical efficacy of EPO
supplementation in AD has been shown in
numerous studies [10–12]. Nevertheless, the
use of EPO has been judged controversially
[10, 13, 14]; moreover, a measurable biomarker
for the possible efficacy of EPO has not yet been
described.
This study aimed to investigate whether a
clinical response to EPO supplementation in AD
patients correlates with an increase in plasma
GLA and DGLA levels. It should be defined
whether GLA and DGLA would, therefore,
represent possible biomarkers. With that,
patients responding to EPO supplementation
with clinical improvement of AD could be
identified by determining GLA and/or DGLA
plasma levels.
METHODS
Study Design
The study was designed as a prospective,
explorative, multi-center, open, non-
controlled pilot trial at five centers in
Switzerland. It was conducted according to
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ICH guidelines for Good Clinical Practice. All
procedures followed were in accordance with
the Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed oral and written
consent was obtained from all patients and/or
their legal representatives for being included in
the study. The study protocol was approved by
the cantonal ethics committees and the
regulatory agency. The study was registered at
ClinicalTrials.gov (Identifier: NCT00878670).
Patients and Clinical Assessments
Patients between 2 and 45 years old were
included into the study if they had AD
according to the criteria of Hanifin and Rajka
[15] with predominant rough and fissured skin
as well as pruritus for at least 2 months. Women
of childbearing potential needed to use a highly
effective method of contraception during the
entire duration of the study. Pregnant or
lactating women were excluded.
The main exclusion factors were the
presence of chronic dermatosis such as
seborrheic dermatitis, contact dermatitis,
nummular eczema, psoriasis, ichthyosis, an
immuno-deficiency or any immunological
disorder, scabies, cutaneous fungal infection,
HIV-associated skin disorders, malignant
diseases, T cell-Lymphoma, Letterer-Siwe-
disease, progressive systemic diseases, serious
internal diseases (e.g., serious de-compensated
diseases of the heart, liver, and/or kidneys, or
diabetes mellitus) or hypersensitivity towards
one of the ingredients in the investigational
product. Study participants who had been
taking part in another study or had taken an
investigational product during the last 4 weeks
before the start of treatment were not allowed
to take part in the study.
The study participants were allowed to
continue to use any medication which they
had been taking prior to the study at the same
dose, unless the medication could be
discontinued or was listed as prohibited
medication. Prohibited medication prior to
study start and during the study were as
follows. Thirty days prior to study start,
physical or psychological therapy, anti-
inflammatory medication to treat AD, and
immuno-modulating medication were not
allowed. Fourteen days prior to study start,
non-steroidal anti-rheumatic drugs, systemic
use of glucocorticosteroids, tranquillizers or
antiemetic agents from the phenothiazine
group were forbidden and 7 days prior to
study start alpha- or beta-blockers, clonidine,
alpha-sympathomimetic medication,
azelastine, levocabastine, or antidepressants
were not allowed to be taken by the patient.
The objective SCORing Atopic Dermatitis
(SCORAD) index [16] and plasma GLA and
DGLA levels were assessed before treatment
(baseline) and 4 and 12 weeks after treatment
initiation. As safety parameters, the occurrence
of adverse events (AEs), hematological and
clinical-chemical laboratory tests, and vital
signs were assessed. A total of 36 patients were
screened and 13 screening failures occurred;
forbidden medication (pimecrolimus,
antidepressants; n = 2), holidays (n = 2),
refusal of blood sampling (n = 1), no interest
to participate (n = 1), not possible to participate
(n = 1), and no reason specified (n = 6).
Study Medication
The study medication (EPOGAM 1000, Zeller
Medical AG, Romanshorn, Switzerland)
contained 932–1,073 mg EPO (Oenothera
seminis oleum), corresponding to 80 mg GLA
per capsule. The dosages were two capsules
twice daily for patients aged 2–12 years and
three capsules twice daily for patients over
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12 years. Treatment duration was 12 weeks.
Treatment compliance was defined as intake of
at least 75% of the trial medication. Rescue
medication including prednicarbate cream
0.25% (Prednitop, Abbott AG, Baar,
Switzerland) and hydroxyzine syrup 2 mg/ml
(Atarax; UCB Pharma, Bulle, Switzerland) was
disposed to coup eczema exacerbations and
pruritus, respectively.
Blood Sample Analysis
The DGLA and GLA measurements were
performed at AZ Biopharm GmbH (Berlin,
Germany). To stabilize fatty acids, butylated
hydroxytoluene was added and blood was
stored at -20 C. As published elsewhere [17],
absolute levels of GLA and DGLA in human
plasma were determined applying a gas
chromatographic method with mass selective
detection. Additionally, safety laboratory
parameters [routine parameters of blood count
and blood chemistry as well as Immunoglobulin
E (IgE) levels] were measured locally at each
investigator’s site laboratory.
Statistics
To compare SCORAD and fatty acid levels at
baseline, week 4 and week 12, data were tested
by non-parametric Wilcoxon Signed Rank Test
for paired samples for the intention-to-treat
(ITT) population. The relationship between the
clinical response (percentage reduction of
objective SCORAD from baseline to last visit)
and the increase in GLA and DGLA in plasma
from baseline to last visit was assessed by linear
regression models in the per-protocol (PP)
population including only patients with
acceptable treatment compliance. The possible
effect of the co-medication on the clinical
improvement (relative change of objective
SCORAD) was assessed using a non-parametric
group comparison (users versus non-users) by
means of Kruskal–Wallis test. The statistical
analysis was performed with the software SPSS
version 19.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
A total of 36 patients were screened, of whom
23 were included in the study (safety
population; 14 females). The mean age was
26.3 years (range 3–58 years). The age groups
were as follows: under 12 years (n = 6), between
12 and 18 years (n = 2), and above 18 years
(n = 15). Eighty-seven percent of the patients
were Caucasian. Two patients were lost to
follow-up, resulting in 21 patients in the ITT
population. From the ITT population, seven
patients had to be excluded because of poor
treatment compliance (\75% of study
medication intake). Thus, the PP population
included 14 patients.
In total, 14 patients of the safety population
(n = 23) had allergic concomitant diseases such
as asthma bronchiale, allergic rhinitis, or
rhinoconjunctivitis. No significant difference
in the SCORAD index between patients of the
PP population (n = 14) with allergic
concomitant diseases (n = 8) and patients
without (n = 6) could be found in a sub-
analysis (data not shown).
Objective SCORAD Significantly Decreased
The clinical efficacy of EPO was assessed in the
ITT population by recording the objective
SCORAD at baseline, 4 weeks and 12 weeks
after initiation of EPO therapy. At baseline,
42.9% of the patients had mild symptoms
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(objective SCORAD \25) and 57.1% had
moderate symptoms (objective SCORAD
25–50), according to Oranje et al. [16]. After
the 12-week treatment period, 93.2% of the
patients had mild symptoms, whereas only
6.8% had moderate symptoms. Accordingly,
the mean objective SCORAD showed a time-
dependent reduction with a statistically
significant decrease after 4 and 12 weeks,
respectively, compared to baseline (Fig. 1;
Supplemental Table 1 in the Electronic
Supplementary Material). With specific focus
on SCORAD parameters, a significant decrease
in both the extent and total intensity of AD
after EPO treatment was noticed (Table 1). In
addition, the intensity of individual AD
symptoms except for weeping/crusting was
significantly reduced. Supplementation of EPO
had no effect on total IgE levels (data not
shown).
Total SCORAD Significantly Decreased
In line with the results obtained for the
objective SCORAD, the clinical efficacy of EPO
could also be confirmed for the total SCORAD.
The mean total SCORAD showed a time-
dependent reduction with a statistically
significant decrease after 4 (P = 0.019) and
12 weeks (P = 0.001), respectively. Results of
all individual SCORAD parameters are
illustrated in Table 1.
Increase in Plasma Fatty Acid Levels
Inversely Correlated with SCORAD
In the ITT population, the plasma levels of both
GLA and DGLA showed a significant increase
over the study period (Fig. 2; Supplemental
Table 1 in the Electronic Supplementary
Material). This increase was most evident from
baseline to week 4, with no relevant further
increase to week 12. For the PP population, it
could be shown that the reduction of the
objective SCORAD was inversely correlated
with the increase in plasma GLA (Fig. 3). In
the ITT population, the correlation of the
objective SCORAD and plasma GLA was not
significant (data not shown) For DGLA, no
significant correlation could be demonstrated
(P = 0.36; data not shown).
Usage of Rescue Medication did not Affect
Study Outcome
While EPO represents a long-term basic therapy
for AD, the usage of concomitant treatment
options reflects the usual practice. Patients were
allowed to use the provided rescue medication
(prednicarbate cream and hydroxyzine syrup), for
example, in cases of severe itching. The influence
of the co-medication was evaluated in the ITT
population (n = 21). During the study, rescue
medication was used by the majority of patients
(71.4%). A total of nine patients used hydroxyzine
(syrup, 10–50 mg orally). Twelve patients used
prednicarbate (cream, 0.25% topically) as rescue
Fig. 1 Objective SCORAD (%, mean ± SEM) in the
intention-to-treat population (n = 21) assessed at baseline
and 4 and 12 weeks after initiation of EPO treatment
(Wilcoxon Signed Rank Test). EPO evening primrose oil,
SCORAD SCORing Atopic Dermatitis
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medication. Six of these patients used both rescue
medications. The treatment duration and dosage
regimens varied quite differently in both rescue
medications (Table 2). However, the patient
groups relying on rescue medication did not
show any significant difference regarding the
improvement of the objective SCORAD
compared to the group without usage of
concomitant anti-pruritic medication (P = 0.20
and P = 0.89, respectively).
Safety
During the study, 26 AEs were recorded in 13
patients. No serious AEs occurred. Only five AEs
were assessed to be related to the study drug
(tiredness, impaired concentration, diarrhea,
abdominal cramps, and pruritus). No clinically
relevant abnormalities of safety laboratory
parameters or vital signs were noticed.
DISCUSSION
This study showed that supplementation with
EPO had significant effects on clinical
improvement of clinical signs in patients with
AD in association with an increase in plasma GLA
and DGLA levels. This is in line with previous
studies, revealing the clinical effect of EPO after
4–8 weeks of treatment [10]. The present study
showed further improvement of AD symptoms
upon 12 weeks, supporting the idea that EPO
should be applied as long-term basic therapy.
Low peripheral blood levels of GLA and
DGLA have been reported in patients with AD
[18]. Supplementation with EPO containing
relevant amounts of GLA resulted in a
significant increase in GLA and DGLA plasma
levels in our AD patient group. Since GLA and
DGLA can be metabolized to 15-HETrE and
PGE1 in the skin, a deficit in GLA might result
Table 1 Elements of the objective and the total SCORAD (mean ± SD) in the intention-to-treat population (n = 21) at
baseline and at last visit (Wilcoxon Signed Rank Test)
SCORAD items Baseline Last visit P value
A: extent of AD (%) 13.7 (12.0) 4.0 (3.6) \0.001
B: total intensity of AD 6.9 (1.9) 4.0 (2.4) \0.001
B1: intensity of erythema 1.4 (0.5) 1.0 (0.7) 0.046
B2: intensity of edema 0.7 (0.7) 0.2 (0.4) 0.021
B3: intensity of weeping/crusting 0.4 (0.7) 0.2 (0.5) 0.470
B4: intensity excoriation 1.1 (0.8) 0.5 (0.6) 0.004
B5: intensity licheniﬁcation 1.5 (0.7) 1.0 (0.9) 0.046
B6: intensity dryness of skin 1.8 (0.8) 1.0 (0.6) 0.003
Objective SCORAD 26.7 (7.6) 14.6 (8.9) \0.001
C: total subjective symptoms
(itching + insomnia, VAS in mm)
51.0 (34.5) 43.5 (49.8) 0.145
Total SCORAD 31.8 (8.7) 19.0 (12.7) \0.002
The objective SCORAD formula is A/5 + 7B/2. The total SCORAD formula is: A/5 + 7B/2 + C, where, A extent (rule of
nine in %) of AD, B sum of intensity of 6 symptoms erythema, edema, weeping/crusting, excoriation, licheniﬁcation, dryness
of skin of AD (B1–B6), and C subjective symptoms (0–20)
AD atopic dermatitis, SCORAD SCORing Atopic Dermatitis, VAS visual analog score
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in a reduced production of these anti-
inflammatory metabolites [5]. Thus, low GLA
levels might contribute to inflammation of
allergic diseases. Accordingly, GLA levels
inversely correlated with total serum IgE levels
[18].
It has been shown that in children with AD
receiving GLA supplementation have a lower
SCORAD compared to the placebo group [19].
The increase in plasma GLA concentration was
significantly inversely correlated with AD
severity [19]. Moreover, a placebo-controlled
study investigating the effect of borage oil
containing at least 23% GLA showed a clinical
improvement of AD, in particular, in those
patients in whom an increase in erythrocyte
DGLA levels was found [20]. In agreement with
these reports, a significant reduction of clinical
signs in a group of pediatric and adult AD
patients treated with EPO as assessed by
objective SCORAD was observed. Moreover,
the increase in GLA plasma levels upon
supplementation with EPO was associated with
a reduction of the objective SCORAD. This
effect was observed as early as 4 weeks after
initiating EPO therapy.
Remarkably, the significance of these
preliminary results could be obtained despite
the small sample size. The difference in plasma
GLA levels might be an appropriate marker to
identify responders. Thus, AD patients
benefitting from EPO could be selected
4 weeks after initiating supplementation and
be given advice to continue EPO
supplementation. Patients without an increase
in plasma GLA after 4 weeks although receiving
EPO supplementation might most likely be
Fig. 2 Plasma GLA (a) and DGLA (b) levels
(mean ± SEM) in the intention-to-treat population
(n = 21) at baseline and 4 and 12 weeks after initiation
of EPO treatment (Wilcoxon Signed Rank Test). DGLA
dihomo-gamma-linolenic acid, EPO evening primrose oil,
GLA gamma-linolenic acid
Fig. 3 Correlation analysis on the per-protocol population
(n = 14) between the change in objective SCORAD (%)
and change of plasma GLA (%) from baseline versus last
visit. GLA gamma-linolenic acid, SCORAD SCORing
Atopic Dermatitis
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regarded as non-responders and recommended
to stop therapy.
The limitation of this study was the open,
non-randomized, non-placebo-controlled
design. An additional linear regression analysis
was applied to further strengthen the
correlation between plasma GLA levels and
clinical response. Since the number of patients
was rather small and the group was
heterogeneous, further studies are required to
evaluate the relation between GLA levels and
AD severity in larger pediatric and adult
cohorts. Such an approach might set a cut-off
level clearly distinguishing between responders
and non-responders.
CONCLUSION
Supplementation therapy with EPO resulted in
a significant increase in plasma GLA and DGLA
levels. The increase in plasma GLA was
associated with an improvement of clinical
signs in patients with AD. Thus, the difference
in GLA levels upon EPO therapy after 4 weeks
could serve as biomarker to identify responders
among AD patients.
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